Antimicrobial Stewardship

This combination antibiotic is indicated for adults with limited or no treatment options, including gram-negative infections. It will be available in the third quarter of this year.

The antimicrobial resistance (AMR) crisis stems from natural microbial adaptation and the lack of new antimicrobials in development. Vulnerable populations worldwide, including within the US, are disproportionately affected, exacerbating the spread of resistance.

Fecal microbiota transplantation emerges as the top treatment, while probiotics show limited effectiveness in preventing CDI recurrence.

The successful implementation of AI into trying to combat resistance will require broader integration efforts, training, and regulatory frameworks.

The agency pointed out that pathogens such as Klebsiella pneumoniae and Escherichia coli (E coli) are problematic for healthcare systems and the general public across Europe.

Levofloxacin was associated with statistically significant reduction in tuberculosis developing in household contacts of persons with multidrug- resistant TB in a meta-analysis, but not in the constituent controlled trials.

Gregory Fox, PhD outlines the trial's challenges, the impact of combining results with the TB Champ trial, and the role of collaboration in strengthening research outcomes.

Gregory Fox, PhD discusses the V Quinn trial's results, exploring levofloxacin’s role in reducing TB incidence and the study's approach to combining data with the TB Champ trial.

Intravenous (IV) push is an attractive option to administer antimicrobial therapy to patients in an efficient and effective manner in a variety of clinical settings. While many advantages to IV push administration exist, clinicians should be mindful of available literature regarding safety profiles, pharmacokinetic/pharmacodynamic characteristics, and clinical data for IV push antimicrobial administration prior to utilizing it in specific patient populations.

Vaccines and treatments are up for approval in early to mid-2025, including a chikungunya vaccine, a meningococcal vaccine, a monoclonal antibody for RSV, and more.

Mackenzie Keintz, MD validate an antibiotic appropriateness metric to enhance UTI treatment in outpatient care, addressing challenges in coding and prescribing accuracy.

An investigational inhibitor, V-161, has been shown to reduce bacterial growth and colonization in an enzyme that is key to enterococcus proliferation.

Oral omadacyline or linezolid was equally efficacious to intravenous dosing for acute bacterial skin infections, and associated with less cost and risks.

In the third installment of our series on preparedness, Gavin Harris, MD, discusses the principles and challenges of biorisk management, focusing on infectious disease threats and containment strategies.

This investment will support the development of a rapid diagnostic platform for neonatal sepsis care by identifying infections and resistance markers within hours.

NACCHO’s CEO Lori Tremmel Freeman discusses efforts and emphasizes the need for federal support and coordination.

Significant value can be offered through the incorporation of stewardship concepts into infection guidelines, but we must also address the risk and challenges it may impose on health care systems.

Here is a novel use of ceftaroline to treat methicillin-resistant Staphylococcus epidermidis ventriculitis in a preterm infant with a ventriculosubgaleal shunt.

CEO Lori Tremmel Freeman discusses NACCHO's capacity-building programs and strategies to strengthen local health departments in addressing evolving public health threats.

Mary Rochelle Smith, MD, Julie J Lee, MD, and Amy Chang, MD, PharmD, share expert strategies for implementing effective clinical decision support tools in practice.

Patrick D Crowley, DO explains the impact of the "skip phenomenon" in Staphylococcus lugdunensis infective endocarditis, linking it to longer hospital stays and higher mortality rates.

Babafela Awosile, DVM, MVSc, PhD, DACVPM, discusses the need for surveillance as blaCTX-M-15 and blaCMY-2 spread in humans, animals, and the environment.

In the second part of our conversation, Abdulwhab Shremo Msdi, PharmD, discusses using this methodology.

How targeting zinc deprivation in VIM-2-expressing bacteria may open new doors for treating multidrug-resistant infections, with azithromycin showing promise.

Study reveals how bacteria secrete natural products that make their competitors vulnerable to viral infection, with potential implications for enhancing phage therapy and shaping microbial ecosystems.